By Beth JoJack — Fact checked by Alexandra Sanfins, Ph.D.
Asthma is a chronic condition affecting the airways that can cause wheezing, coughing, tightness in the chest, and shortness of breath.
An asthma attack occurs when these symptoms become severe.
About one in 13 individuals in the United States have asthma, according to the Asthma and Allergy Foundation of America.
Asthma cannot be cured but it can be treated. Individuals with asthma often carry quick-relief inhalers to use in case of an attack.
The inhalers contain medications known as bronchodilators. They relax the muscles in the lungs and widen the airways.
People with asthma are often also prescribed long-term control medications, such as Inhaled corticosteroids or leukotriene modifiers, which modify the production of leukotrienes. Leukotrienes are inflammatory molecules that are released by mast cells during an asthma attack. They are responsible for broncho constriction.
Health practitioners sometimes prescribe oral corticosteroids for asthma flare-ups to reduce inflammation in the airways. However, oral corticosteroids cause both short and long-term side-effects and risks, such as high blood pressure and cataracts.
Of Americans who have asthma, between 5% to 10% have severe or difficult-to-control asthma, according to the American Lung Association.
Doctors say some people with difficult-to-control asthma may not be using their inhalers correctly or using them as often as recommended.
A study led by researchers at the RCSI University of Medicine and Health Sciences looked at the use of a technological device that measures acoustic or sound-wave signals from the inhaler to objectively assess how a person uses his or her inhaler.
The study, published in The Lancet Respiratory Medicine, reported that when information from a digital device is integrated into a clinical decision platform, then medication doses are less likely to be increased. This procedure led to a modest improvement in medication adherence among people with asthma.
Health practitioners sometimes prescribe biologics for people with severe asthma.
Biologics are part of a newer group of drugs that mimic molecules that live in cells. In people with asthma, biologics target specific inflammatory pathways, reducing inflammation.
Biologics can reduce asthma flare-ups, improve lung function, and reduce the need for oral corticosteroid use. Biologics are also often expensive.
About 15 years ago, Dr. Richard Costello, the lead investigator of this latest study and a professor at the RCSI University of Medicine and Health Sciences, ran a program for people with severe asthma.
“We were really restricted in access to the biologics because of costs,” he told Medical News Today.
Earlier in his career, Costello had listened to a speaker who speculated that people frequently fail to take their asthma medications correctly.
“It really stuck in my mind that if I was going to be… making decisions on a limited number of people to get a biologic, I needed to be sure that the people I was selecting were the best fit,” he explained.
About a decade ago, Costello teamed up with an engineer. “We developed this acoustic bass device that allows us to tell both when the inhaler was used and also how it was used,” he said.
With the device, doctors could look at objective information about whether patients were using their inhalers at the frequency prescribed and using them correctly. If patients were using the inhalers as directed, health practitioners could feel more comfortable prescribing biologics.
“We think it’s kind of an equitable way to access biologics,” Costello said.
Researchers carried out the study in 10 severe asthma clinics in Ireland and England with 200 participants who had severe or difficult-to-control asthma.
Eligible participants had to be at least 18 years old, diagnosed with asthma and prescribed inhaled corticosteroids in combination with a twice-daily inhaled corticosteroids (ICS) long-acting beta-agonist for at least 12 months.
Within the previous year, participants also needed to have had a severe flare-up, requiring being treated with oral corticosteroids, visits to an emergency room, or admittance to a hospital.
People were excluded from the study for a number of factors, including if they were already on biologics.
Over the course of a 32-week study, participants had three nurse-led education visits and three physician-led visits where their treatment could be adjusted.
Participants in the active group used an Inhaler Compliance Assessment (INCA) device, which was attached to the top of an inhaler. The device made an audio recording each time the inhaler is used.
Signal processing algorithms classified the quality of each inhalation. If the inhaler wasn’t primed, if there was an exhalation into the inhaler before inhalation, or if the inhalation flow peak was less than 40 liter per minute, the algorithm marked the use as an error.
Additionally, participants recorded twice daily digital peak expiratory flow (ePEF).
Participants in the control group had adherence and exacerbations accessed by pharmacy records, health practitioners watching inhaler technique, and use of a questionnaire.
At nurse-led education visits, participants in the active group received visual biofeedback on adherence and inhaler user error. They were also shown the relationships between treatment use and their ePEF.
During the nurse-led education visits for participants in the control group, participants heard a standard education program that included a discussion of the nature of asthma.
During the physician-led visits for participants in the active group, doctors were provided with asthma and adherence data that was factored into a decision algorithm on how to adjust treatment.
During the physician-led visits for participants in the control group, doctors relied on traditional methods such as visual assessment of the inhaler technique to decide whether to adjust treatment.
Of the active group, 14% were prescribed a net increase in treatment, while 32% of the control group were prescribed a net increase in treatment.
Of the active group, 31% were able to reduce their medication. In the control group, 18% were able to do this.
Of the 102 patients in the active group, 11 needed add-on biological therapy. Of the 98 control patients, 21 needed add-on biological therapy.
Dr. Jimmy Johannes, a pulmonologist and critical care medicine specialist at MemorialCare Long Beach Medical Center in California who was not involved with the study, told Medical News Today that he would be interested to read about future clinical trials about the INCA device.
“We’ve known to a certain degree that adherence can be a big issue with our asthma patients,” Johannes said. “But to see one, the degree that it might be an issue, and also two, how much adherence improvement can result in reducing the treatment burden and reducing the use of biologics.”
The point of creating the device, Costello pointed out, isn’t to give doctors a way to catch patients not following directions.
“We’re looking to see if we can support people,” he said. “If they’re struggling to understand their condition or they’re struggling to use their inhaler correctly, it’s not fair to judge them as being non-adherent. It’s not fair that insurance companies put incredible barriers on people accessing biologics.”
This article originally appeared here and was republished with permission.